New combo therapy aims to stop returning brain tumors
NCT ID NCT04659811
First seen Apr 18, 2026 · Last updated May 06, 2026 · Updated 2 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to precise radiation (stereotactic radiosurgery) can help control recurrent meningioma, a type of brain tumor that has come back after prior treatment. About 35 adults with grade II or III meningioma will receive the combination. The goal is to see if this approach improves the time without tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.